Abbott Laboratories said Tuesday its drug Humira met key treatment goals in a late-stage study focusing on ulcerative colitis.
Ulcerative colitis is a chronic inflammatory bowel disease affecting nearly 700,000 people in the U.S. Humira — the company's best-selling product — is already approved to treat autoimmune disorders including rheumatoid arthritis, plaque psoriasis and Crohn's disease
In the latest study, Humira prompted remission in 16.5 percent of patients, compared with 9.3 percent on placebo after eight weeks. The study included 494 patients.
Shares of Abbott fell 2 cents to $52.64 in afternoon trading.